Test Code BCGR Immunoglobulin Gene Rearrangement, Blood
Reporting Name
Immunoglobulin Gene Rearrange, BUseful For
Determining whether a B-cell or plasma cell population is polyclonal or monoclonal using whole blood specimens
Identifying neoplastic cells as having B-cell or plasma cell differentiation
Monitoring for a persistent neoplasm by detecting an immunoglobulin gene rearrangement profile similar to one from a previous neoplastic specimen
Performing Laboratory

Specimen Type
Whole bloodShipping Instructions
Specimen must arrive within 7 days of collection.
Specimen Required
Container/Tube:
Preferred: Lavender top (EDTA)
Acceptable: Yellow top (ACD)
Specimen Volume: 4 mL
Collection Instructions:
1. Invert several times to mix blood.
2. Send whole blood specimen in original tube. Do not aliquot.
Specimen Minimum Volume
1 mL
Specimen Stability Information
Specimen Type | Temperature | Time |
---|---|---|
Whole blood | Ambient (preferred) | 7 days |
Refrigerated | 7 days |
Special Instructions
Reference Values
An interpretive report will be provided.
Day(s) Performed
Monday through Friday
Test Classification
This test was developed using an analyte specific reagent. Its performance characteristics were determined by Mayo Clinic in a manner consistent with CLIA requirements. This test has not been cleared or approved by the US Food and Drug Administration.CPT Code Information
81261-IGH (Immunoglobulin heavy chain locus) (eg, leukemias and lymphomas B-cell), gene rearrangement analysis to detect abnormal clonal populations; amplified methodology (eg. polymerase chain reaction)
81264-IGK (Immunoglobulin kappa light chain locus) (eg, leukemia and lymphoma, B-cell) gene rearrangement analysis, evaluation to detect abnormal clonal populations
LOINC Code Information
Test ID | Test Order Name | Order LOINC Value |
---|---|---|
BCGR | Immunoglobulin Gene Rearrange, B | 61113-7 |
Result ID | Test Result Name | Result LOINC Value |
---|---|---|
18229 | Final Diagnosis: | 34574-4 |
608948 | Signing Pathologist | 19139-5 |
Interpretation
An interpretive report will be provided.
The interpretation of the presence or absence of a predominant immunoglobulin gene rearrangement profile is sometimes subjective. These results must always be interpreted in the context of other clinicopathologic information to determine the significance of the result.
The detection of a clonal immunoglobulin gene rearrangement by this test is not synonymous with the presence of a B-cell or plasma cell neoplasm.
Clinical Reference
1. van Dongen JJ, Langerak AW, Brüggemann M, et al. Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98-3936. Leukemia. 2003;17(12):2257-2317. doi:10.1038/sj.leu.2403202
2. Gazzola A, Mannu C, Rossi M, et al. The evolution of clonality testing in the diagnosis and monitoring of hematological malignancies [published correction appears in Ther Adv Hematol. 2014 Oct;5(5):181]. Ther Adv Hematol. 2014;5(2):35-47. doi:10.1177/2040620713519729
3. Kokovic I, Jezersek Novakovic B, Novakovic S. Diagnostic value of immunoglobulin ? light chain gene rearrangement analysis in B-cell lymphomas. Int J Oncol. 2015;46(3):953-962. doi:10.3892/ijo.2014.2790
4. Wang J, Zhao S, Niu T, et al. Prognostic relevance of immunoglobulin heavy chain rearrangement and immunoglobulin kappa light chain rearrangement in patients with diffuse large B cell lymphoma. Oncologist. 2025;30(3):oyaf016. doi:10.1093/oncolo/oyaf016
Report Available
5 to 7 daysMethod Name
Polymerase Chain Reaction (PCR)
Forms
1. Hematopathology Patient Information (T676)
2. If not ordering electronically, complete, print, and send a Hematopathology/Cytogenetics Test Request (T726) with the specimen.